Selank and Semax

Selank and semax were both developed in Russia. They have a long record of study in eastern European labs. Selank is a synthetic copy based on tuftsin, a natural immune peptide. Semax is a synthetic copy of the ACTH 4-7 fragment. That is the fourth to seventh part of a hormone called ACTH.

Both are short peptides studied for their effects on the brain. Both are sold for research in the Core Health GB range. That includes the selank nasal formulation and the semax nasal formulation.

Selank comes from tuftsin, a small active peptide. Tuftsin sits inside part of an antibody called IgG. Tuftsin has been studied for its immune effects. The selank copy tries to keep those effects. It also adds activity relevant to the brain.

Semax is a more changed structure. It is based on the ACTH 4-7 fragment. It has been extended and stabilised to last longer in tests. The ACTH 4-7 region carries proline-rich sequences. These are known to affect memory-linked behaviour in animals.

The origin of both peptides matters to researchers. It explains their names and how they are grouped. Selank is called a tuftsin copy. Semax is called an ACTH 4-7 copy. A guide to peptide structure and classification covers how short peptides are placed by chain length.

Interest in selank centres on anxiety-type and immune signalling. Studies report that selank changes genes tied to brain rewiring. It can also change levels of a protein called BDNF. BDNF is closely linked to learning and brain plasticity. It is a common marker in neuropeptide research. That is because it links the peptide to real changes in brain signals.

Semax research has also focused on brain rewiring. Published studies describe semax raising BDNF and other growth signals. They also describe effects on new nerve cell growth in test models. So both peptides are studied mainly through molecules that may support how the synapse works.

A large part of the selank studies is behavioural. Standard lab tests used for anxiety-type responses are the elevated plus maze and open field. In these, selank has been reported to lower anxiety-linked behaviour in rodents.

The anxiety-type finding is usually set within a wider talk of the peptide's effects on brain chemicals. These include the GABA and serotonin pathways. Researchers often pair behaviour tests with chemical or gene-readout measures. That builds a fuller picture of what the peptide does.

Semax has the longer record in cognition research. The literature describes better learning and memory in animals after semax. These gains are often put down to the peptide's effect on growth and rewiring signals. They are not tied to one single receptor target.

Because both peptides touch the same plasticity pathways, some groups treat them as a pair. Selank is used for anxiety-type and immune-adjacent questions. Semax is used for cognitive and memory-focused work.

The split is useful but not strict. Both act within the same growth-signal systems. Studies that pair them can compare how two different copies act on shared markers, such as BDNF. That helps separate peptide-specific effects from common neuropeptide responses.

Read as a whole, the literature reports that both peptides change plasticity-linked markers. Selank shows repeatable effects in tests linked to anxiety-type responses in rodents. Semax shows a longer record of learning and memory findings in animals. These are steady, well-grounded findings in test systems.

What the literature does not report is any set proof of clinical use. Most work stays at the preclinical stage. Researchers should draw conclusions about the pathways, not about any real-world use.

The evidence base for both peptides is large but uneven. A lot of it sits in Russian-language papers. English studies exist and are growing. Yet much of the founding work is not indexed like mainstream western journals. Researchers should keep this structure in mind. They should judge each study on quality and repeatability.

Neither peptide has proven clinical effect. Most work stays at the preclinical and early-clinical stages. For study design, both are well-described tools. Their main value is the repeatable nature of the plasticity readouts.

One practical point follows. Anyone writing a review on selank or semax needs to search beyond standard English databases. They must account for reports in Russian-language journals or conference notes. Translation and reporting rules vary. So the careful researcher applies the same checks as to any material, looking for controls, sample size and replication across groups.

For researchers planning work on these pathways, both nasal forms are supplied by Core Health GB for research. Nasal forms are used in studies that avoid injected routes. That can matter where nasal delivery is itself the research variable. All material should be handled under the lab's own rules and used only for research.

For primary literature, search PubMed for selank and semax. See the certificate of analysis guidance for how to read purity data on research material.

All products referenced in this article are supplied strictly for laboratory research use only. They are not medicines, are not licensed or approved for human or veterinary consumption, and must not be administered to humans or animals. Nothing in this article is medical advice. Researchers are responsible for operating within their own institution's and jurisdiction's applicable regulations.